title: Acarbose is an effective adjunct to dietary therapy in the treatment of hypertriglyceridaemias.
abstract: OBJECTIVE
  In diabetics, acarbose causes a reduction of blood glucose and triglyceride levels. The aim of this study was to assess the effect of this drug in non diabetic subjects with hypertriglyceridaemia.
  
  
  METHODS
  Thirty non diabetic patients with hypertriglyceridaemia type IIb or IV (24 males, six females; mean age 51.1+/-10.2 years) were studied. They were stratified into two groups depending on their basal triglyceride concentration (group A: triglyceride values </=4.5 mmol l-1; group B triglyceride values >4.5 mmol l-1 ). Treatment consisted of 4 week courses of diet plus acarbose (50 mg twice daily) alternating with 4 weeks of diet alone for a total period of 16 weeks.
  
  
  RESULTS
  Mean triglyceride values decreased significantly during the first and third cycles of therapy, i.e. diet plus acarbose treatment cycles in both patient groups. Group A also had significant reductions in total cholesterol and HDL cholesterol concentrations after completion of the acarbose treatment. Reduction of triglyceride levels was observed after both acarbose courses in patients affected by hypertriglyceridaemia type IIb. A marked reduction of triglyceride concentrations was achieved by patients affected by hypertriglyceridaemia type IV after the second acarbose course only.
  
  
  CONCLUSIONS
  Diet alone did not reduce triglyceride concentrations to normal values in our patients. The data suggest that acarbose is a useful adjunct to dietary control in non-diabetic patients affected by severe hypertriglyceridaemia.
authors.affiliation: Department of Internal Medicine and Geriatrics, University of Catania, Catania, Italy. malaguar@mbox.unit.it
authors.forename: M
authors.initials: M
authors.lastname: Malaguarnera
authors.forename: I
authors.initials: I
authors.lastname: Giugno
authors.forename: P
authors.initials: P
authors.lastname: Ruello
authors.forename: M
authors.initials: M
authors.lastname: Rizzo
authors.forename: M
authors.initials: M
authors.lastname: Motta
authors.forename: G
authors.initials: G
authors.lastname: Mazzoleni
mesh_terms: D020909:Acarbose / Q000008:administration & dosage* / Q000009:adverse effects; D000277:Adjuvants, Pharmaceutic / Q000008:administration & dosage*; D001786:Blood Glucose / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002784:Cholesterol / Q000378:metabolism; D005260:Female; D006801:Humans; D015228:Hypertriglyceridemia / Q000145:classification / Q000178:diet therapy* / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood*
chemical_list: D000277:Adjuvants, Pharmaceutic; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D014280:Triglycerides; D002784:Cholesterol; D020909:Acarbose